Weight-loss drugs face legal action over eye stroke risks

Hundreds of consumers are suing manufacturers of GLP-1 receptor agonists, alleging these medications may increase the risk of a rare, vision-damaging condition called NAION, or nonarteritic anterior ischemic optic neuropathy. While researchers have identified a potential link, studies are observational and do not confirm causation. The FDA is reviewing the evidence, but currently has not issued safety warnings, whereas European regulators have classified NAION as a "very rare" side effect. Patients are advised to consult their healthcare providers before discontinuing or starting GLP-1 medications.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article